5月21日主题复盘 | 黄金再度大涨，固态电池表现，医药持续活跃

Market Overview - The Shanghai Composite Index experienced narrow fluctuations, while the ChiNext Index showed stronger performance, and the North Exchange 50 reached a new historical high. The trading volume today was 1.21 trillion [1] - Gold stocks surged collectively, with companies like Laishen Tongling hitting the daily limit and Xiaocheng Technology rising over 10%. The solid-state battery concept also saw a breakout, with stocks like Jinlongyu, Guoxuan High-Tech, and Lingpai Technology hitting the daily limit. Pharmaceutical stocks remained active, with SanSheng Guojian, Shuotai Shen, and Haichen Pharmaceutical also hitting the daily limit [1] Key Highlights Gold Sector - The gold sector saw significant gains, with Laishen Tongling and Western Gold hitting the daily limit, and Xiaocheng Technology and Zijin Mining also experiencing substantial increases. Spot gold prices surpassed $3,300 per ounce for the first time since May 9 [4] - Domestic gold jewelry prices increased, with notable rises in prices from companies like Chow Sang Sang and Lao Miao Gold [4] Solid-State Battery Sector - The solid-state battery sector experienced a strong rally, with Jinlongyu and Guoxuan High-Tech both hitting the daily limit. Jinlongyu announced a procurement order for high-energy density solid-state battery cells, achieving a density of 500Wh/kg [6] - Guoxuan High-Tech announced the completion of a pilot line for solid-state batteries and introduced new products, with over four clients already testing the new quasi-solid-state battery [6][7] - The global solid-state battery shipment is projected to reach 5.3 GWh in 2024, with significant growth expected by 2030, where the market for solid-state electrolytes alone could exceed 210 billion [8] Pharmaceutical Sector - The pharmaceutical sector saw a notable increase, with SanSheng Guojian achieving three consecutive daily limits. The company entered a licensing agreement with Pfizer for a dual-specific antibody, showcasing the potential of innovative drugs in the market [9][10] - The domestic innovative drug industry is expected to reach a turning point by 2025, shifting from capital-driven to profit-driven growth, indicating potential investment opportunities [11]